SCHEMBL55404

SCHEMBL55404

CN(CCCN)C(=O)OC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38
CA14 Q9ULX7 2/20 0.37
CTSK P43235 3/20 0.35
PDK2 Q15119 1/20 0.34
AAK1 Q2M2I8 1/20 0.33
GBA1 P04062 1/20 0.33
METAP2 P50579 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31
TRPV4 Q9HBA0 1/20 0.31
CHRM2 P08172 1/20 0.31
FPR3 P25089 1/20 0.31
FPR2 P25090 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA7 P43166 1/20 0.31
CACNA1G O43497 1/20 0.31
CACNA1B Q00975 1/20 0.31
CACNA1C Q13936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28028259 0.98 HDAC6 (0.37) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL1654128 0.94 CA14 (0.40) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL23728825 0.93 CHRM2 (0.39) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL18391125 0.93 CHRM2 (0.42) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL22291496 0.93 CHRM2 (0.42) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL2722798 0.93 CHRM2 (0.42) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL28909787 0.93 CHRM2 (0.42) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL7775532 0.90 CHRM2 (0.39) HDAC6HDAC1HDAC2CA14PDK2
SCHEMBL34414 0.88 HDAC6 (0.36) HDAC6HDAC1HDAC2CA14CTSK
SCHEMBL17770771 0.88 CA14 (0.49) HDAC6HDAC1HDAC2CA14CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 453 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103789055-A M15 methanol gasoline vapor pressure stabilizer GANSU SANGTIAN CLEAN ENERGY DEV CO LTD 2014-05-14 CN claimed
EP-4746963-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
EP-4747260-A1 MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
EP-4747243-A1 LIGANDS AND COMPOSITIONS AND METHODS OF USE THEREOF Baylor College of Medicine (US) 2026-05-27 EP disclosed
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-02 US disclosed
US-20260070901-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CAMBRIDGE ENTPR LTD (GB) 2026-03-12 US disclosed
EP-4076466-B1 MODULATORS OF CULLIN 3 ADAPTOR KBTBD4 AS ANTI-CANCER COMPOUNDS UNIV MONTREAL (CA) 2026-03-11 EP disclosed
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BOLT BIOTHERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-4687854-A2 LIPIDS AND LIPID-LIKE COMPOUNDS FOR THERAPEUTIC LIPID NANOPARTICLE (LNP) DELIVERY Flagship Labs 114, Inc. (US) 2026-02-11 EP disclosed
EP-4676537-A1 COMPOUNDS OF DRUGS WITH AN ALBUMIN BINDING MOIETY Ascendis Pharma A/S (DK) 2026-01-14 EP disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed
WO-2003010164-A1 ARYLSULFONAMIDE DERIVATIVES AS C-JUN-N-TERMINAL KINASES (JNK'S) INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-02-06 WO disclosed
WO-2002068377-A1 OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS Dompé S.p.A. (IT) 2002-09-06 WO disclosed
US-6063791-A N-benzenesulfonyl-L-proline derivatives, method for preparing and therapeutic use FOURNIER INDUSTRIE ET SANTE (FR) 2000-05-16 US disclosed
EP-0540334-B1 Fibrinogen receptor antagonists MERCK & CO INC (US) 1996-01-03 EP disclosed
WO-1995017397-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1995-06-29 WO disclosed
US-5416099-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1995-05-16 US disclosed
US-5389631-A A piperidinyl quinazoline or 1,3-benzodiazepine antiagglomerants of blood MERCK & CO., INC. (US) 1995-02-14 US disclosed
US-5272158-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1993-12-21 US disclosed
EP-0540334-A1 Fibrinogen receptor antagonists MERCK & CO. INC. (US) 1993-05-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092057-A1 BCL-XL/BCL-2 DEGRADERS AND USES THEREOF BCL2L2, BCL2A1, BCL2L1 HDAC6 1205/4885HDAC1 620/4885HDAC2 841/4885
US-20260070901-A1 NOVEL COMPOUNDS AS CK2 INHIBITORS CSNK1A1, CSNK2A3, CSNK1G1 HDAC6 1199/4885HDAC1 317/4885HDAC2 291/4885
US-12570610-B2 Macromolecule-supported aminobenzazepine compounds BCL6, CLTB, MET HDAC6 623/4885HDAC1 265/4885HDAC2 1163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.